Pharmaceutico-Analytical and Exploratory Study of Shila Sindoor in the Treatment of Bronchial Asthma (Tamaka Swasa)

A Pharmaceutico Analytical And Exploratory Trial Of Shila Sindoor In The Management Of Tamak Swasa (Bronchial Asthma) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094171

Enrollment

Registered

2025-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-60 years irrespective of sex. 2. Patients having cardinal sign and symptoms as in Ayurvedic classics and contemporary medicine. 3. Night symptoms more than twice per month but less than once a week. 4. Patients who meet reversibility criteria. 5. FEV1 is grater then 80 pracent of the predicted value. 6. Diagnosed mild and moderate cases of asthma (GINA) without any co morbidity.

Exclusion criteria

Exclusion criteria: 1. Patients having other associated diseases like LVFURTI, Bronchiectasiscases of tuberculosis, IL.D 2. Patients having major systemic illness. 3. Patients having Renal and Hepatic disease. 4. Patients with HIV Positive. 5. Pregnant and lactating mothers should be excluded. 6. Patients without written consent form.

Design outcomes

Primary

Measure	Time frame
change in subjective parametersTimepoint: 30 days	—

Secondary

Measure	Time frame
Improvememt in quality of life of patientTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Manoj Barupal

PGIA JODHPUR

manishagoyal29@gmail.com8890242078

Outcome results